You are here

Article Text

Article menu

Download PDFPDF

Brief communication
Lung Screen Uptake Trial: results from a single lung cancer screening round
  1. Mamta Ruparel1,
  2. Samantha L Quaife2,
  3. Jennifer L Dickson1,
  4. Carolyn Horst1,
  5. Sophie Tisi1,
  6. Helen Hall1,
  7. Magali Taylor3,
  8. Asia Ahmed3,
  9. Penny Shaw3,
  10. Stephen Burke4,
  11. May-Jan Soo4,
  12. Arjun Nair3,
  13. Anand Devaraj5,
  14. Karen Sennett6,
  15. Stephen W Duffy7,
  16. Neal Navani1,8,
  17. Angshu Bhowmik9,
  18. David R Baldwin10,
  19. Sam M Janes1
  1. 1 Lungs for Living Research Centre, UCL Respiratory, University College London, London, England, UK
  2. 2 Research Department of Behavioural Science and Health, University College London, London, UK
  3. 3 Department of Radiology, University College London Hospitals NHS Foundation Trust, London, London, UK
  4. 4 Department of Radiology, Homerton University Hospital NHS Foundation Trust, London, London, UK
  5. 5 Department of Radiology, Royal Brompton Hospital, London, UK
  6. 6 Killick Street Health Centre, London, UK
  7. 7 Wolfson Institute of Preventive Medicine, Barts and London, London, UK
  8. 8 Thoracic Medicine Department, University College London Hospitals NHS Foundation Trust, London, London, UK
  9. 9 Respiratory Medicine, Homerton University Hospital NHS Foundation Trust, London, London, UK
  10. 10 Respiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK
  1. Correspondence to Dr Sam M Janes, Lungs for Living Research Centre, UCL Respiratory, University College London, London WC1E 6JJ, UK; s.janes{at}ucl.ac.uk

Abstract

The Lung Screen Uptake Trial tested a novel invitation strategy to improve uptake and reduce socioeconomic and smoking-related inequalities in lung cancer screening (LCS) participation. It provides one of the first UK-based ‘real-world’ LCS cohorts. Of 2012 invited, 1058 (52.6%) attended a ‘lung health check’. 768/996 (77.1%) in the present analysis underwent a low-dose CT scan. 92 (11.9%) and 33 (4.3%) participants had indeterminate pulmonary nodules requiring 3-month and 12-month surveillance, respectively; 36 lung cancers (4.7%) were diagnosed (median follow-up: 1044 days). 72.2% of lung cancers were stage I/II and 79.4% of non-small cell lung cancer had curative-intent treatment.

  • lung cancer
  • imaging/CT MRI etc
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

https://doi.org/10.1136/thoraxjnl-2020-214703

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @mamta_ruparel, @LUNGRADIOLOGIST

    • Contributors All authors were involved in the design and/or conduct of the study or the interpretation of the results. All authors contributed to and approved the final manuscript.

    • Funding This study was part of the Lung Screen Uptake Trial project, which was funded by a National Awareness and Early Diagnosis Initiative (NAEDI) project grant awarded by Cancer Research UK (CRUK) and a consortium of funders (Department of Health (England); Economic and Social Research Council; Health and Social Care R&D Division, Public Health Agency, Northern Ireland; National Institute for Social Care and Health Research, Wales; Scottish Government) (SLQ and SMJ). SMJ is a Wellcome Trust Senior Fellow in Clinical Science (WT107963AIA). SMJ is supported by the Rosetrees Trust, the Roy Castle Lung Cancer Foundation, the Stoneygate Trust, the Welton Trust, the Garfield Weston Trust and the UCLH Charitable Foundation. This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centre’s funding scheme (NN and SMJ). SLQ is supported by a CRUK Postdoctoral Fellowship (C50664/A24460).

    • Competing interests SMJ, MR, JLD, CH, ST and HH are supported by funding for a large trial of low dose CT screening, called the ‘SUMMIT Study’ by GRAIL Inc. SLQ and NN collaborate on the SUMMIT Study. SMJ has received honoraria from AstraZeneca, BARD1 Bioscience and Janssen for being an Advisory Board Expert and travel to a US conference. SMJ received grant funding from Owlstone for a separate research study and has a family member who has a financial association with AstraZeneca. MR has received travel funding for a conference from Takeda and an honorarium for planning and speaking at educational meetings from AstraZeneca.

    • Patient consent for publication Not required.

    • Ethics approval This study is part of the Lung Screen Uptake Trial (LSUT), which was granted ethical approval by the City Road and Hampstead NHS Research Ethics Committee (REC; reference: 15/LO/1186) and was registered with ClinicalTrials.gov (NCT02558101) and the International Standard Registered Clinical/soCial sTudy Number (ISRCTN21774741).

    • Provenance and peer review Not commissioned; externally peer reviewed.